Pharmacokinetics and tolerability of bosentan in patients with mild liver impairment.

被引：0
|
作者：
van Giersbergen, P [1 ]
Popescu, G [1 ]
Dingamanse, J [1 ]
机构：
[1] Actelion Pharmaceut Ltd, APEX Res, Allschwil, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90665-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P84 / P84
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment.
    Lai, Catherine
    Cole, Diane
    Shovlin, Margaret
    Widemann, Brigitte C.
    Dunleavy, Kieron
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Pharmacokinetics of eslicarbazepine acetate in patients with moderate liver impairment.
    Maia, Joana
    Potgieter, J. Henk
    Almeida, Luis
    Soares-da-Silva, P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1192 - 1192
  • [3] Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
    van Giersbergen, PLM
    Popescu, G
    Bodin, F
    Dingemanse, J
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (01): : 15 - 22
  • [4] Pharmacokinetics of frovatriptan in patients with renal impairment.
    Cohen, AF
    van der Post, J
    Sacks, S
    Marsh, J
    Buchan, P
    CEPHALALGIA, 1999, 19 (04) : 365 - 365
  • [5] Pharmacokinetics of pioglitazone in patients with renal impairment.
    Edwards, G
    Eckland, DJA
    DIABETOLOGIA, 1999, 42 : A230 - A230
  • [6] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [7] Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.
    Burstein, AH
    Lee, PID
    Gajjar, D
    Zhou, H
    Soo, Y
    Pesco-Koplowitz, L
    Hantson, L
    Woestenborghs, R
    Young, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 189 - 189
  • [8] Eribulin mesylate pharmacokinetics in patients with hepatic impairment.
    Witteveen, P.
    Marchetti, S.
    Mergui-Roelvink, M.
    Reyderman, L.
    Copelu, W.
    Wanders, J.
    Jenner, A.
    Edwards, G.
    Schellens, J. H.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Pharmacokinetics of eslicarbazepine acetate in patients with renal impairment.
    Almeida, Luis
    Potgieter, J. Henk
    Maia, Joana
    Soares-da-Silva, P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1193 - 1193
  • [10] EFFECT OF FIMASARTAN ON PHARMACOKINETICS IN PATIENTS WITH RENAL IMPAIRMENT.
    Kim, S.
    Shin, D.
    Kim, Y. S.
    Cho, S. H.
    Jang, I. J.
    Lee, H.
    Yu, K. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S72 - S72
12345